Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

GDCOLCA

Financiado

Cerrado

Understanding gamma delta T cells in colon cancer metastasis

Cancer is the leading cause of death in the world. Immunotherapy is having a major impact in counteracting these cancer-related deaths, since the activity of anti-tumour immune cells can be enhanced to kill cancer. Unfortunately,... ver más

31/05/2020

BEATSON INSTITUTE...

195K€

Presupuesto del proyecto: 195K€

Líder del proyecto

BEATSON INSTITUTE FOR CANCER RESEARCH LBG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-05-31

MSCA-IF-2017: Individual Fellowships

I+D

Cerrada hace 7 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

BEATSON INSTITUTE FOR CANCER...

195.45K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

GammaDeltaTME Cellular and molecular regulators of the pleiotropic activit... 160K€ Cerrado

SAF2017-86782-R ABORDANDO EL CANCER COLORRECTAL DESDE EL MICROAMBIENTE DEL T... 460K€ Cerrado

TREATLIVMETS Treating Liver Metastasis 10M€ Cerrado

RTC2019-006860-1 Ensayo clínico fase I/II: nuevo enfoque terapéutico para el... 1K€ Cerrado

PID2021-125501OB-I00 MODELOS PRECLINICOS PERSONALIZADOS PARA NEOPLASIAS MALIGNAS... 393K€ Cerrado

CRC-MTOs Colorectal Cancer Mouse Tumor Organoids as Pre clinical Mode... 150K€ Cerrado

Duración del proyecto: 25 meses Fecha Inicio: 2018-04-16
Fecha Fin: 2020-05-31

Líder del proyecto

BEATSON INSTITUTE FOR CANCER RESEARCH LBG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 195K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cancer is the leading cause of death in the world. Immunotherapy is having a major impact in counteracting these cancer-related deaths, since the activity of anti-tumour immune cells can be enhanced to kill cancer. Unfortunately, immunotherapy does not work for every patient, so we must understand how other immune cells participate in cancer progression to design new immunotherapies that may benefit a greater number of patients. One particular type of immune cell, called gamma/delta T cells, was recently shown by my Host to promote breast cancer metastasis via IL-17, an important pro-tumour cytokine. However, the significance of gamma/delta T cells and IL-17 in other cancer metastasis settings remains unclear. In this proposal, I will address this point using a newly developed sophisticated colorectal cancer metastasis model. This novel mouse model shows 100 percent penetration of metastasis, of which 80 percent is to the liver, similar to human colorectal metastasis. Using this metastasis model, I will: 1. Clarify characteristics of gamma/delta T cells in colorectal cancer metastasis, 2. Assess if depletion of gamma/delta T cells by a neutralizing antibody as well as crossing the model with gamma/delta T cell-deficient mice would reduce the occurrence of metastasis, and 3. Examine the involvement of BTNL1, which is a specific activator for anti-tumorigenic IFN-producing gamma/delta T cells in the intestine. The role of BTNL1 in any cancer setting and the importance of IL-17-producing gamma/delta T cells in colon cancer metastasis is largely unexplored. Addressing our goal to understand the role of these gamma/delta T cells in colon cancer metastasis, I will newly acquire expertise and technical skills in both immunology and cancer biology as well as have experience in excellent collaboration with several laboratories. This proposal will identify additional targets for immunotherapy that may help patients with metastatic colon cancer.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores